LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Large Joints and Extremities/New Study: MR-HIFU Effectively Destroys Osteoid Osteoma
Large Joints and Extremities

New Study: MR-HIFU Effectively Destroys Osteoid Osteoma

September 18, 2017 2 min read Premium comments

Advertisement

New Study: MR-HIFU Effectively Destroys Osteoid Osteoma
Karun Sharma, M.D., Ph.D., director of Interventional Radiology at Children’s National Health System, poses with 10-year-old Niyati Shah and 16-year-old Alfredo Coreas, the first two children with osteoid osteoma successfully treated in the U.S. as part of an innovative research study using noninvasive MR-HIFU. / Courtesy of Children’s National Health System
Secondary

A new clinical trial has shown how a bone tumor known as osteoid osteoma can be safely and successfully treated using an incisionless surgery method called magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU).

Physicians from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National Health System in Washington, D.C. have published their work, “Comparison of Noninvasive High-Intensity Focused Ultrasound with Radiofrequency Ablation of Osteoid Osteoma,” in the August 17, 2017 edition of The Journal of Pediatrics.

According to an August 24, 2017 Children’s National news release, “…the study compares nine patients, ages 6 to 16 years old, who were treated for osteoid osteoma using MR-HIFU with a nine-patient historical control group, ages 6 to 10 years old, who were treated at Children’s National using radiofrequency ablation (RFA) surgery, the standard treatment at most U.S. hospitals. The study results show that treatment using MR-HIFU is feasible and safe for patients, eliminating the incisions or exposure to ionizing radiation that is associated with the RFA procedure…”

“High-intensity focused ultrasound therapy uses focused sound wave energy to heat and destroy the targeted tumor under MRI guidance. This precise and controlled method does not require a scalpel or needle, greatly reducing the risk of complications like infections and bone fractures. It is also a faster treatment option, with expected total procedure time of 90 minutes or less. In the U.S., MR-HIFU is used to treat uterine fibroids and painful bone metastases from several types of cancer in adults, but has not previously been used in children.”

Karun Sharma, M.D., Ph.D., director of Interventional Radiology at Children’s National, was the principal investigator for the osteoid osteoma trial. Dr. Sharma told OTW, “Our early results demonstrate that MR-HIFU ablation for painful osteoid osteoma is a completely noninvasive treatment option with clinical improvement similar to CT-guided radiofrequency ablation. It also appears that pain relief and quality of life improvement is similar to treatment with radiofrequency ablation—the current gold standard treatment.”

“We would like orthopedic surgeons to know that MRI guided HIFU (MR-HIFU) is a completely non-invasive and radiation free treatment option for patients with osteoid osteoma. It may offer the same clinical results as radiofrequency ablation—the current gold standard treatment. In the future, this focused ultrasound treatment may also be used for other painful bone lesions as well.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy